Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy
Granzyme B als prädiktiver Biomarker für therapeutische Ergebnisse bei Patient:innen mit nicht-kleinzelligem Lungenkarzinom unter Anti-PD-1-Therapie
Frontiers in Oncology · 09.11.2026 · 16
DOI: 10.3389/fonc.2026.1964690 ↗Auf einen Blick
Bei 64 Patient:innen mit fortgeschrittenem NSCLC unter Nivolumab waren Granzyme-B-Spiegel und zytotoxische Lymphozyten bei Responder:innen höher als bei Non-Respondern. Höhere Verläufe waren mit besserem PFS und OS assoziiert.
Fragestellung
Kann Granzyme B bei Patient:innen mit fortgeschrittenem NSCLC unter Nivolumab therapeutische Ergebnisse anzeigen?
Methode
Prospektive Beobachtungsstudie bei 64 Patient:innen mit fortgeschrittenem NSCLC und 30 gesunden Kontrollen; Blutentnahmen zu T0, T1 und T2; ELISA, Durchflusszytometrie und Kaplan-Meier-Analysen.
Ergebnisse
Responder:innen zeigten höhere PD-L1-Expression im Tumor und Zunahmen von CD3+CD56+ NKT-like-Zellen, NK-Zellen, CD8+Granzyme B+ T-Zellen und Ki67+CD8+PD-1+ T-Zellen. Plasma-Granzyme B war höher (P < 0,0001).
Schlussfolgerung der Autor:innen
Die longitudinale Messung von Plasma-Granzyme-B-Kinetik und zytotoxischer Lymphozytenaktivierung ist laut Autor:innen ein nützlicher nicht-invasiver pharmakodynamischer Indikator der systemischen Anti-Tumor-Immunaktivierung unter Nivolumab.
Kernaussagen
- Granzyme B war bei Responder:innen höher als bei Non-Respondern und Kontrollen
- Höhere Granzyme-B-Verläufe korrelierten mit besserem PFS und OS
- Autor:innen sehen Granzyme B als dynamischen Marker der Immunaktivierung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Kriti Jain und 5 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed the management of advanced non-small cell lung cancer (NSCLC). However, durable clinical benefit is restricted to a subset of patients, necessitating reliable, minimally invasive pharmacodynamic biomarkers to monitor treatment engagement and response.
Methods
In this prospective observational study evaluating an expanded patient cohort overlapping with our previous reporting, 64 patients with advanced NSCLC receiving second-line nivolumab monotherapy and 30 healthy controls were analyzed. Peripheral blood samples were collected longitudinally at baseline (T0), 6–8 weeks (T1), and 14–16 weeks (T2) post-treatment initiation. Plasma Granzyme B (GrmB) concentrations (pg/mL) were quantified via ELISA, and cell subset-specific intracellular expression was characterized using multiparametric flow cytometry. Archival tumor tissue was evaluated for PD-L1 expression, tumor mutational burden, microsatellite instability, and TP53 status. Exploratory in-vitro experiments evaluated A549 and NCI-H23 cell lines exposed to direct nivolumab treatment (0-200 µg/mL). Longitudinal dynamics were evaluated using repeated-measures linear mixed-effects models with multiplicity adjustments, and survival outcomes (OS and PFS) were assessed using Kaplan–Meier.
Results
Responders (R) demonstrated significantly higher baseline tumor PD-L1 expression compared to non-responders (NR). Flow cytometric immunophenotyping revealed dynamic expansions in responders, including a three-fold increase in CD3+CD56+ NKT-like cells, a two-fold increase in NK cells, a ten-fold elevation in CD8+Granzyme B+ T cells, and a 2.5-fold increase in proliferating Ki67+CD8+PD-1+ T cells. Circulating plasma Granzyme B concentrations were markedly elevated in responders compared to non-responders and healthy controls (P < 0.0001). In exploratory cell-line assays, direct nivolumab exposure increased Granzyme B secretion and expression in A549 and NCI-H23 cells without impacting short-term cell viability. While higher circulating Granzyme B trajectory correlated with superior progression-free and overall survival, multivariable Cox regression indicated that Granzyme B kinetics serve as a dynamic marker of active immune engagement rather than an independent pre-treatment predictive biomarker when adjusting for overall clinical response.
Conclusion
Longitudinal monitoring of plasma Granzyme B kinetics and cytotoxic lymphocyte activation particularly CD3+CD56+ NKT-like and effector CD+ T-cell subsets provides a valuable non-invasive pharmacodynamic indicator of systemic anti-tumor immune activation during nivolumab therapy in advanced NSCLC.
Zitieren
APA
Jain, K., Singh, A., Aggarwal, S., Awasthi, A., Ganguly, N. K., & Madan, E. (2026). Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1964690
Vancouver
Jain K, Singh A, Aggarwal S, Awasthi A, Ganguly NK, Madan E. Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1964690
BibTeX
@article{Jain2026,
author = {Jain, Kriti and Singh, Asees and Aggarwal, Shyam and Awasthi, Amit and Ganguly, Nirmal Kumar and Madan, Evanka},
title = {Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1964690}
}
EUVIMED